Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Jimaitong** is an orally administered investigational traditional Chinese medicine tablet being developed for stage 1 primary hypertension with the traditional Chinese medicine liver-fire hyperactivity pattern. It was evaluated in a randomized, double-blind, multicenter, placebo-controlled Phase 2 trial, CTR20131805. Published network-pharmacology work characterizes it as a multicomponent herbal product and proposes potential involvement of AGE-RAGE, PI3K-Akt, TNF, adrenergic signaling in cardiomyocytes, and focal-adhesion pathways; these are computational mechanistic hypotheses rather than clinically validated direct molecular targets. ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/2b17d9eee8be413eb53e852676c68d3f))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jimaitong.